ExIthera Pharmaceuticals supports the creation of antithrombotic and stroke prevention medications.
ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 2, 2012 | Series A | $2M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Access BridgeGap Ventures | — | Series A |